Copenhagen, 29 April 2014 – Zealand Pharma A/S (Zealand) (CVR no. 20 04 50 78) (NASDAQ OMX Copenhagen: ZEAL) announces its un-audited interim report for the period from 1 January – 31 March 2014, a quarter which saw important advances for the company’s portfolio of peptide based medicines and a positive financial net result of DKK 29/EUR 4 million.
Help employers find you! Check out all the jobs and post your resume.
